218 related articles for article (PubMed ID: 31929430)
21. Clinical significance of subcategory and severity of chronic graft-versus-host disease evaluated by National Institutes of Health consensus criteria.
Sato T; Ichinohe T; Kanda J; Yamashita K; Kondo T; Ishikawa T; Uchiyama T; Takaori-Kondo A
Int J Hematol; 2011 Apr; 93(4):532-541. PubMed ID: 21465116
[TBL] [Abstract][Full Text] [Related]
22. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
[TBL] [Abstract][Full Text] [Related]
23. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.
Czerw T; Labopin M; Giebel S; Socié G; Volin L; Fegueux N; Masszi T; Blaise D; Chaganti S; Cornelissen JJ; Passweg J; Maertens J; Itälä-Remes M; Wu D; Mohty M; Nagler A
Cancer; 2018 Jun; 124(12):2523-2533. PubMed ID: 29603136
[TBL] [Abstract][Full Text] [Related]
24. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
Lee SJ; Klein JP; Barrett AJ; Ringden O; Antin JH; Cahn JY; Carabasi MH; Gale RP; Giralt S; Hale GA; Ilhan O; McCarthy PL; Socie G; Verdonck LF; Weisdorf DJ; Horowitz MM
Blood; 2002 Jul; 100(2):406-14. PubMed ID: 12091329
[TBL] [Abstract][Full Text] [Related]
25. Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation.
Hao B; Gao S; Sang YW; Wang L; Meng XQ; You JY
J Zhejiang Univ Sci B; 2019 Oct.; 20(10):849-860. PubMed ID: 31489804
[TBL] [Abstract][Full Text] [Related]
26. Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.
Moon JH; Hamad N; Sohn SK; Uhm J; Alam N; Gupta V; Lipton JH; Messner HA; Seftel M; Kuruvilla J; Kim DD
Ann Hematol; 2017 May; 96(5):805-815. PubMed ID: 28214979
[TBL] [Abstract][Full Text] [Related]
27. Improvement of quality of life in patients with steroid-refractory chronic graft-versus-host disease treated with the mTOR inhibitor everolimus.
Lutz M; Kapp M; Einsele H; Grigoleit GU; Mielke S
Clin Transplant; 2014 Dec; 28(12):1410-5. PubMed ID: 25287756
[TBL] [Abstract][Full Text] [Related]
28. Real-Time PCR Analysis of Chimerism in T Cell Subsets as an Early Predictor of Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplantation.
Guz K; Nasiłowska B; Tomaszewska A; Orzińska A; Smolarczyk-Wodzyńska J; Krzemienowska M; Hałaburda K; Przybylski M; Jędrzejczak WW; Mariańska B; Brojer E
Ann Transplant; 2015 Dec; 20():720-8. PubMed ID: 26632547
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of autoantibody expression in allogeneic stem-cell recipients.
Moon JH; Lee SJ; Kim JG; Chae YS; Kim SN; Kang BW; Suh JS; Lee KS; Sohn SK
Transplantation; 2009 Jul; 88(2):242-50. PubMed ID: 19623021
[TBL] [Abstract][Full Text] [Related]
30. Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation.
Partanen J; Hyvärinen K; Bickeböller H; Bogunia-Kubik K; Crossland RE; Ivanova M; Perutelli F; Dressel R
Front Immunol; 2020; 11():575492. PubMed ID: 33193367
[TBL] [Abstract][Full Text] [Related]
31. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.
Balon J; Hałaburda K; Bieniaszewska M; Reichert M; Bieniaszewski L; Piekarska A; Pawłowski R; Hellmann A
Bone Marrow Transplant; 2005 Jun; 35(11):1083-8. PubMed ID: 15821766
[TBL] [Abstract][Full Text] [Related]
32. Hydrogen in Patients With Corticosteroid-Refractory/Dependent Chronic Graft-Versus-Host-Disease: A Single-Arm, Multicenter, Open-Label, Phase 2 Trial.
Qian L; Liu M; Shen J; Cen J; Zhao D
Front Immunol; 2020; 11():598359. PubMed ID: 33324415
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.
Pérez-Simón JA; Encinas C; Silva F; Arcos MJ; Díez-Campelo M; Sánchez-Guijo FM; Colado E; Martín J; Vazquez L; Del Cañizo C; Caballero D; San Miguel J
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1163-1171. PubMed ID: 18804047
[TBL] [Abstract][Full Text] [Related]
34. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome.
Zecca M; Prete A; Rondelli R; Lanino E; Balduzzi A; Messina C; Fagioli F; Porta F; Favre C; Pession A; Locatelli F;
Blood; 2002 Aug; 100(4):1192-200. PubMed ID: 12149197
[TBL] [Abstract][Full Text] [Related]
35. [The clinical characteristics of polyserositis as main presentation of chronic graft-versus-host rejection disease after allogeneic hematopoietic stem cell transplantation].
Wang Q; Li Y; Qiu Z; Xu W; Sun Y; Wang L; Wang M; Liu W; Dong Y; Ou J; Wang W; Liang Z; Wang Q; Cen X; Ren H
Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):394-7. PubMed ID: 25146408
[TBL] [Abstract][Full Text] [Related]
36. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WJ; Weisdorf DF
Biol Blood Marrow Transplant; 2001; 7(5):265-73. PubMed ID: 11400948
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling-based identification of CD28 and PI3K as new biomarkers for chronic graft-versus-host disease.
Lai P; Weng J; Lu Z; Guo R; Luo C; Wu S; Ling W; Geng S; Du X
DNA Cell Biol; 2011 Dec; 30(12):1019-25. PubMed ID: 21682596
[TBL] [Abstract][Full Text] [Related]
38. Pentraxin-3 levels in graft-versus-host disease during allogeneic hematopoietic stem cell transplantation.
Doehn JM; Winkler A; Kuzmina Z; Hladik A; Greinix H; Knapp S; Robak O
Exp Hematol; 2016 Oct; 44(10):917-23. PubMed ID: 27403536
[TBL] [Abstract][Full Text] [Related]
39. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis.
Fante MA; Holler B; Weber D; Angstwurm K; Bergler T; Holler E; Edinger M; Herr W; Wertheimer T; Wolff D
Ann Hematol; 2020 Sep; 99(9):2181-2190. PubMed ID: 32715339
[TBL] [Abstract][Full Text] [Related]
40. The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.
Wang Z; Yin C; Zhang W; Tang W; Song X; Hu X; Ni X; Qiu H; Yang J; Hu J; Wang J
Ann Hematol; 2019 Jul; 98(7):1765-1773. PubMed ID: 30993416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
